These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38201560)

  • 1. Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma.
    Alshammari K; Alotaibi FM; Alsugheir F; Aldawoud M; Alolayan A; Algarni MA; Sabatin F; Mohammad MF; Alosaimi A; Sanai FM; Odah H; Alshehri AS; Aldibasi OS; Alrehaily S; Al Saleh AS
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma.
    Cheung KS; Lam LK; Seto WK; Leung WK
    Liver Cancer; 2021 Nov; 10(6):606-614. PubMed ID: 34950183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
    Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma.
    Chu PY; Chan SH
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy.
    Kang X; Wang J; Kang X; Bai L
    BMC Cancer; 2023 Aug; 23(1):787. PubMed ID: 37612634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
    Li Y; Liu W; Chen J; Chen Y; Guo J; Pang H; Zhang W; An C; Li C
    Cancer Med; 2024 Jan; 13(1):e6836. PubMed ID: 38196277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.
    Li Z; Li N; Li F; Zhou Z; Sang J; Jin Z; Liu H; Han Q; Lv Y; Liu Z
    Oncotarget; 2016 May; 7(18):26168-80. PubMed ID: 27034168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
    Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
    Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus.
    Hsu YC; Chen CH; Huang HF; Lee YT; Wu MC; Su CW; Chou HC; Wang LF; Lee HS; Lin SW; Hsu PN; Wu YM; Sheu JC; Weng MT
    Transplantation; 2023 Jul; 107(7):1492-1501. PubMed ID: 36380450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model.
    Wei Y; Wang Y; Liu N; Qi R; Xu Y; Li K; Feng Y; Shi B
    Front Pharmacol; 2021; 12():820446. PubMed ID: 35115949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
    J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
    Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
    Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
    Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
    Front Immunol; 2022; 13():876048. PubMed ID: 35812439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.